Congressmembers Langworthy, Schrier Introduce Bipartisan Bill to Lower Prescription Drug Costs by Expanding Access to Biosimilars
Those unnecessary studies can cost millions of dollars, delay competition, and keep lower-cost treatment options … required, providing greater certainty and helping avoid unnecessary delays. The legislation is supported by a broad coalition